Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTirzepatide does not typically increase blood pressure. Clinical trial data suggest the opposite: most participants saw modest reductions in systolic blood pressure over the course of treatment, even without significant changes to antihypertensive medication. That said, individual responses vary, and anyone with a blood pressure condition should discuss this with their prescriber before starting. Mounjaro is a prescription-only medicine requiring a clinical assessment — a prescriber decides whether it is appropriate for you based on your full health picture, including cardiovascular history.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. Across all tirzepatide dose groups, participants saw statistically meaningful reductions in systolic blood pressure compared with placebo. At the 15mg dose, average systolic reductions were in the range of 6–8 mmHg. Diastolic changes were more modest. These findings are consistent with what we know about weight loss generally: shedding a significant proportion of body weight tends to ease the mechanical and metabolic load on the cardiovascular system, and blood pressure tends to follow.
Whether tirzepatide has a direct blood-pressure effect beyond weight reduction is still being studied. The current evidence points to weight loss as the primary driver, which matters clinically: it means the benefit accumulates as treatment continues rather than appearing immediately after the first injection. If you want to understand how dose progression relates to overall outcomes, the detail on whether increasing the Mounjaro dose increases weight loss is worth reading alongside this.
The NICE appraisal of tirzepatide (TA1026) acknowledged improvements in cardiometabolic risk factors, including blood pressure, as part of its clinical-evidence review. So the picture from both the primary trial and the regulatory assessment is consistent: blood pressure generally goes down, not up.
Honest answer: for a small minority, yes, at least transiently. The Mounjaro SmPC on the electronic Medicines Compendium notes an increase in resting heart rate as a recognised effect of tirzepatide, and elevated heart rate can sometimes accompany a perceived rise in blood pressure for some individuals, even when measured blood pressure remains stable or falls. This is not the same as hypertension and does not usually require stopping treatment, but it is worth monitoring.
There is also the question of nausea and vomiting, particularly in the first weeks on a new dose. Significant fluid loss through repeated vomiting can cause blood pressure to fluctuate. This is one reason the prescribing schedule starts low, and if you are curious about what to expect at that early stage, our page on Mounjaro 5mg explains how that part of the journey works before the dose that does the metabolic work. You can read more about how prescribers decide when to increase the Mounjaro dose and why that pacing matters clinically.
People already on antihypertensive medication are arguably the group who need the most careful monitoring. If blood pressure falls significantly with weight loss and medication stays unchanged, the combined effect can push readings too low. That is not a reason to avoid tirzepatide; it is a reason to keep your GP informed and to have your blood pressure checked regularly. At our clinical team, GP notification in line with GPhC guidance is a standard part of every patient's care, not an optional extra.
NHS guidance on weight-management injections recommends that people with cardiovascular conditions are assessed carefully before starting treatment, and that monitoring continues throughout. This is not specific to blood pressure, it reflects the fact that tirzepatide produces meaningful physiological changes, and those changes need to be tracked by someone who knows your full medical history.
For people whose blood pressure sits at the boundary of normal or who are on multiple antihypertensive medicines, that monitoring conversation often happens at the dose-increase stage, and our page covering how Mounjaro dose increases work sets out what that process involves in practice. Our prescribers review your case before every dose progression, not a rubber stamp, a genuine clinical re-check. Details on what drives that decision are covered in the reasoning behind Mounjaro dose increases.
A separate but related question comes up often: does tirzepatide affect blood sugar as well as blood pressure? If that is on your mind, the evidence on whether the 2.5mg starting dose lowers blood sugar is laid out clearly. Blood pressure and blood glucose are both part of the metabolic picture that weight-loss treatment changes over time.
One thing our prescribers hear regularly is something like: "I was expecting a side effect and instead my GP said my blood pressure had come down, should I be worried?" It is a fair reaction. Unexpected good news can feel suspicious. But the data support it, and your prescriber should be adjusting your other medications accordingly if that happens. If you have concerns, the frequently asked questions section covers many of the monitoring queries people bring to us.
First: measure properly. A single home reading taken when you are anxious, rushed or immediately after activity is not a reliable signal. If you are seeing consistent readings that are higher or lower than your baseline, note them with dates and times and raise them with your prescriber at your next check-in, or sooner if the readings concern you.
Second: do not adjust your antihypertensive doses without clinical advice. That applies in both directions, if your blood pressure has fallen, stopping your medication without guidance could still leave you at risk of rebound. Your prescriber or GP is the right person to make that call.
Third: if you experience severe headache, chest pain, or blurred vision alongside high blood pressure readings, that is a reason to seek urgent medical attention, not to wait for a consultation. Similarly, symptoms of very low blood pressure (dizziness, fainting, feeling faint when standing) should be reported promptly. You can report any suspected side effects directly to the MHRA through the Yellow Card scheme.
For anyone weighing up whether tirzepatide is appropriate given their cardiovascular history, or exploring the broader range of options, the weight-loss treatments page is the starting point for a free consultation with our prescribers, the place where your specific picture, including your blood pressure history, gets properly assessed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.